Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

Debiopharm announces the poster presentations of preclinical data for Debio 0123 and clinical data for Debio 1143 and Debio 1347

Lausanne, Switzerland – April 1, 2019 – Debiopharm, ( a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR inhibitor) and clinical exploratory results for Debio 1143 (IAP[1] inhibitor) at the 2019 Annual AACR meeting in Atlanta, Georgia. These abstract presentations are part of Debiopharm’s ongoing oncology programs to investigate the anti-tumor activity and toxicity profile of innovative compounds aimed at treating a broad variety of cancer types.

“These results from our multiple ongoing oncology programs are giving us more insight into the potential of integrating specialized, targeted compounds into current therapeutic strategies.”
– Gregoire Vuagniaux, Director of Translational Pharmacology, Debiopharm International SA

AACR 2019 Abstract Presentations

Debio 0123

Abstract n°4423:  Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123 

Date and Time: Tue, April 2nd, 1:00-5:00pm

Debio 1143

Abstract n°5001: Open-label, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the SMAC mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck

Date and Time: Wed, April 3rd, 8:00-12:00pm

Debio 1347

Abstract n°4881: Molecular screening of patients with FGFR alterations for a phase 1 (ph1) study with the selective FGFR inhibitor (FGFRi) Debio 1347

Date and Time: Wed, April 3rd, 8:00-12:00pm – Section 19

Debiopharm International’s commitment to cancer patients

Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing and clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe.

Find out about our currently clinical trials at

Visit us

Follow us @DebiopharmNews

[1] IAP= Inhibitor of Apoptosis Proteins